Gerber reboots whey protein formula petition
This article was originally published in The Tan Sheet
Executive Summary
Nestle Infant Nutrition asks FDA to allow a qualified health claim that 100-percent whey-protein partially hydrolyzed infant formula "may reduce the risk of developing the most common allergic disease of infancy -- atopic dermatitis" in infants not exclusively breastfed. The subsidiary of Florham Park, N.J.-based Gerber Products adds in a May 14 citizen 1petition that partially hydrolyzed formulas are not meant to treat existing food allergy symptoms. FDA posted the petition July 21. In 2005, FDA denied a request by Nestle Infant Nutrition, then a Nestle USA division, for a food allergy QHC for whey protein formula (2"The Tan Sheet" May 22, 2006). The firm says its resubmitted petition has a reworded claim and includes additional supporting science
You may also be interested in...
FDA Denies Claim Linking Hydrolyzed Infant Formula To Reduced Allergies
There is "no credible scientific evidence" to support a qualified health claim linking consumption of 100% partially hydrolyzed whey protein infant formula (PHF-W) to a reduced risk of the development of food allergies, FDA concludes in a May 11 letter to petitioner Nestlé USA
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.